XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS’ EQUITY
6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
Stock-Based Compensation
The following table summarizes the components of stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the periods indicated:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Cost of revenues (exclusive of depreciation and amortization)$15,416 $14,732 $31,427 $14,308 
Selling, general and administrative expenses17,694 13,161 40,262 20,697 
Total$33,110 $27,893 $71,689 $35,005 
Stock Options
Stock option activity under the Company’s plans is set forth below:
 Number of
Options 
Weighted Average
Exercise Price 
Aggregate
Intrinsic Value 
Weighted Average
Remaining Contractual Term (in years)
Options outstanding at January 1, 2023
1,923 $98.92 
Options granted108 $298.44 
Options exercised(241)$29.62 
Options forfeited(1)$317.56 
Options outstanding at June 30, 2023
1,789 $120.20 $218,382 3.7
Options vested and exercisable as of June 30, 2023
1,506 $87.39 $216,710 2.7
Options expected to vest as of June 30, 2023
265 $294.39 $1,613 8.7
As of June 30, 2023, $29.9 million of total remaining unrecognized stock-based compensation cost related to unvested stock options, net of estimated forfeitures, is expected to be recognized over the weighted-average remaining requisite service period of 2.4 years.

Restricted Stock and Restricted Stock Units
Service-Based Awards
The table below summarizes activity related to the Company’s equity-classified and liability-classified service-based awards for the six months ended June 30, 2023:
Equity-Classified
Equity-Settled
Restricted Stock Units
Liability-Classified
Cash-Settled
Restricted Stock Units
 
Number of
Shares 
Weighted Average Grant Date
Fair Value Per Share 
Number of
Shares 
Weighted Average Grant Date
Fair Value Per Share 
Unvested service-based awards outstanding at January 1, 2023
916 $291.19 99 $257.74 
Awards granted488 $297.77 36 $299.00 
Awards modified(15)$278.52 15 $305.59 
Awards vested(298)$267.70 (44)$238.41 
Awards forfeited/cancelled(41)$302.53 (4)$239.38 
Unvested service-based awards outstanding at June 30, 2023
1,050 $300.66 102 $287.88 
As of June 30, 2023, $253.6 million of total remaining unrecognized stock-based compensation cost related to service-based equity-classified restricted stock units (“RSUs”), net of estimated forfeitures, is expected to be recognized over the weighted-average remaining requisite service period of 2.9 years.
As of June 30, 2023, $19.8 million of total remaining unrecognized stock-based compensation cost related to service-based liability-classified cash-settled RSUs, net of estimated forfeitures, is expected to be recognized over the weighted-average remaining requisite service period of 2.6 years.
The liability associated with the service-based liability-classified RSUs as of June 30, 2023 and December 31, 2022, was $0.8 million and $10.2 million, respectively, and was classified as Accrued compensation and benefits expenses in the condensed consolidated balance sheets.
Performance-Based Awards
The table below summarizes activity related to the Company’s equity-classified performance-based awards for the six months ended June 30, 2023:
Equity-Classified
Equity-Settled
Restricted Stock
Equity-Classified
Equity-Settled
Restricted Stock Units
 
Number of
Shares 
Weighted Average Grant Date
Fair Value Per Share 
Number of
Shares 
Weighted Average Grant Date
Fair Value Per Share 
Unvested performance-based awards outstanding at January 1, 2023
9 $165.87 15 $412.60 
Awards vested(9)$165.87 (1)$438.26 
Awards forfeited/cancelled— — (1)$363.93 
Unvested performance-based awards outstanding at June 30, 2023
 $ 13 $413.14 
As of June 30, 2023, $2.5 million of total remaining unrecognized stock-based compensation cost related to performance-based equity-classified RSUs is expected to be recognized over the weighted-average remaining requisite service period of 2.2 years.

2021 Employee Stock Purchase Plan
The 2021 Employee Stock Purchase Plan ("ESPP") enables eligible employees to purchase shares of EPAM’s common stock at a discount at the end of each designated offering period, which occurs every six months in April and November. The purchase price is equal to 85% of the fair market value of a share of EPAM’s common stock on the first date of an offering or the date of purchase, whichever is lower. During the three and six months ended June 30, 2023, the ESPP participants purchased 77 thousand shares of common stock under the ESPP. During the three and six months ended June 30, 2022, the ESPP participants purchased 55 thousand shares of common stock under the ESPP.
The Company recognizes compensation expense related to share issuances pursuant to the ESPP on a straight-line basis over the six-month offering period. For the three and six months ended June 30, 2023, the Company recognized $3.4 million and $6.5 million, respectively, of stock-based compensation expense related to the ESPP. For the three and six months ended June 30, 2022, the Company recognized $3.7 million and $5.4 million, respectively, of stock-based compensation expense related to the ESPP. As of June 30, 2023, total unrecognized stock-based compensation cost related to the ESPP was $4.3 million, which is expected to be recognized over a period of 0.3 years.
Commitments for Future Equity Awards
In connection with the Company’s acquisitions of businesses as discussed in Note 3 “Acquisitions”, EPAM enters into agreements that contractually commit it to granting equity awards at future dates. The agreements are unique to each acquisition and terms vary to specify the number of future awards to be issued or a monetary value that will be settled with equity awards valued at future stock prices.
As of June 30, 2023, the Company has commitments to grant up to $26.2 million of equity awards with the number of awards to be determined based on future stock prices. These awards contain performance criteria that will determine the number of future awards to be issued and there is a service-based vesting requirement after the grant date associated with these awards. As these awards are considered granted for accounting purposes, in determining the expense, the Company adjusts the expected settlement based on the probability of achievement of the performance criteria. Related to these awards, the amount of stock-based compensation expense recorded in the condensed consolidated statements of income for the three months ended June 30, 2023 was not material.
As of June 30, 2023, the Company has issued 2 thousand performance-based equity-classified RSUs which are not considered granted for accounting purposes as the future vesting conditions have not yet been determined.
Share Repurchases
On February 13, 2023, the Board of Directors authorized a share repurchase program for up to $500.0 million of the Company's outstanding common stock. EPAM may repurchase shares of its common stock on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The timing and total amount of stock repurchases will depend upon business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. The share repurchase program has a term of 24 months, may be suspended or discontinued at any time, and does not obligate the company to acquire any amount of common stock.
During the three and six months ended June 30, 2023, the Company repurchased 195 thousand and 225 thousand shares of its common stock for $41.4 million and $49.9 million, respectively, in cash. All of the repurchased shares have been retired. As of June 30, 2023, a remaining balance of $450.1 million was available for purchases of the Company’s common stock under the share repurchase program authorized by the Company’s Board of Directors.